RARE-09. EFFICACY AND SAFETY OF DABRAFENIB + TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG)

BACKGROUND: Current treatment outcomes for patients with recurrent HGG are poor, with median progression-free survival (PFS) and overall survival (OS) of 2.5 and 7.5 months, respectively. Dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor) resulted in an intracranial overall response rate (ORR)...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Neuro Oncol
मुख्य लेखकों: Wen, Patrick, Alexander, Stein, Yung-Jue, Bang, van den Bent, Martin, Gazzah, Anas, Dietrich, Sascha, de Vos, Filip, van Linde, Mayra, Lai, Albert, Chi, Andrew, Prager, Gerald, Campone, Mario, von Bubnoff, Nikolas, Fasolo, Angelica, Lopez-Martin, Jose, Mookerjee, Bijoyesh, Boran, Aislyn, Burgess, Paul, Rangwala, Fatima, Subbiah, Vivek
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2018
विषय:
Abstracts
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217670/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.986
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन